Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- OCS
- Price
- 16.75
- Stock movement up
- +0.60 (3.72%)
- Company name
- Oculis Holding AG Ordinary shares
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 702.58M
- Ent value
- 697.33M
- Price/Sales
- 1077.57
- Price/Book
- 7.38
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 43.41%
- 3 year return
- 19.69%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
OCS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1077.57 |
| Price to Book | 7.38 |
| EV to Sales | 1069.52 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 41.95M |
| EPS (TTM) | -1.66 |
| FCF per share (TTM) | -1.20 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 652.00K |
| Gross profit (TTM) | -34.70M |
| Operating income (TTM) | -68.13M |
| Net income (TTM) | -69.62M |
| EPS (TTM) | -1.66 |
| EPS (1y forward) | -1.58 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -5321.78% |
| Operating margin (TTM) | -10449.08% |
| Profit margin (TTM) | -10678.07% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 35.63M |
| Net receivables | 1.78M |
| Total current assets | 111.49M |
| Goodwill | 0.00 |
| Intangible assets | 12.21M |
| Property, plant and equipment | 1.75M |
| Total assets | 125.61M |
| Accounts payable | 4.89M |
| Short/Current long term debt | 1.24M |
| Total current liabilities | 27.72M |
| Total liabilities | 30.38M |
| Shareholder's equity | 95.23M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -50.16M |
| Capital expenditures (TTM) | 178.00K |
| Free cash flow (TTM) | -50.34M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -73.11% |
| Return on Assets | -55.43% |
| Return on Invested Capital | -72.87% |
| Cash Return on Invested Capital | -52.68% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 16.32 |
| Daily high | 16.89 |
| Daily low | 16.19 |
| Daily Volume | 48K |
| All-time high | 22.91 |
| 1y analyst estimate | 28.24 |
| Beta | 0.01 |
| EPS (TTM) | -1.66 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| OCS | S&P500 | |
| Current price drop from All-time high | -26.89% | -12.89% |
| Highest price drop | -40.31% | -56.47% |
| Date of highest drop | 27 Mar 2023 | 9 Mar 2009 |
| Avg drop from high | -9.54% | -11.07% |
| Avg time to new high | 30 days | 12 days |
| Max time to new high | 436 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
702.58M
Marketcap category
Small-cap
Description
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Employees
36
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partner